IL-23

#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
First head-to-head trial to show #PsA joint outcome superiority BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%. @RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD

Links:

Jiha Lee @JihaRheum( View Tweet )
Double targeted therapy in refractory SpA/PsA. 76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics. Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit. ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
🧬 Does spine vs knee enthesis differ immunologically? Translational scRNAseq study: YES! Spine produces more IL-23 but shows attenuated IL-17 response vs knee #POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
🧲 Does GUS+GOL combo beat GUS alone on MRI in PsA? YES for joints - AFFINITY Phase 2a RCT: greater MRI inflammation reduction in 91pts #OP0186 #EULAR2026 @RheumNow https://t.co/9eIS6lh7WN

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

Can we intercept PsA? Retro study 394 PSO pts 17 yrs follow-up 86 PsA TNFi linked to higher PsA incidence vs IL- MoA TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11% After adjustment IL-17i HR 0.35 IL-23i HR 0.17 Needs prospective confirmation! #OP072 #EULAR2026 https://t.co/88RaukjLjY

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Small interventional synovial biopsy precision medicine study CD117 high pts n=15 = better response to IL17i or IL23i inhibition vs. TNFi w/ -DAPSA -13.5, -12.8 vs. -7.5 respectively Higher BL levels of tissue inflammation in Responders vs. NR More robust study design needed https://t.co/7jNff6lUJ6

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
💊 Oral IL-23Ri for #PsA #PsO? ICONIC RCT (n=216): Yes! Icotrokinra improves pain & disease activity at week 16 #POS0052 #EULAR2026 @RheumNow https://t.co/PA4O36h02Y

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Nail #PsA, hard to treat and often overlooked. APEX trial: guselkumab achieved 43% ↓ in nail severity score (mNAPSI) vs 16% worsening on placebo at wk 24, plus PASI 100 in ~39% vs 11%. IL-23 inhibition delivering where pts often struggle most. @RheumNow #EULAR2026 POS0471

Jiha Lee @JihaRheum( View Tweet )

💉 Risankizumab durable in #PsA? #POS0047 3 RCT n=964 KEEPsAKE Yes! ACR50 ~37% & MDA ~34% @w244 no new safety signals 💪 #EULAR2026 @RheumNow https://t.co/911Fi9vxfP

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
🤔 GUS or IL-17i for #PsA? #POS0045: RW study: Both! ~76% persistence & similar effectiveness 1141 pts @12mo #PsABIOnd 🌍 #EULAR2026 @RheumNow https://t.co/PyuaH5B5V1

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Guselkumab in erosive #PsA: ACR20 68% vs 47% placebo, structural damage progression ↓ across subgroups regardless of sex, BMI, MTX use, or joint counts. Highest inflammation and erosion burden? Biggest benefit. IL-23i holds up where it matters most. @RheumNow #EULAR2026 POS0480

Jiha Lee @JihaRheum( View Tweet )

IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045

Jiha Lee @JihaRheum( View Tweet )

What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

EULAR19.abstract.jpg (keep)

EULAR 2026: Industry Press Releases

Jack Cush, MD

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic

Read Article
PsA.Xray_.Erosion.Cup_.jpg

Guselkumab gets FDA Nod for X-ray Protection

Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). 

Read Article
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
H2H.BKZ.RZB

BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA

Jack Cush, MD

UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 results compared to risankizumab (RKB) adults with active psoriatic

Read Article
Biologic.choice.MD_.jpeg (keep)

Breaking the Rules: Dual-Advanced Combinations in Rheumatology

Jack Cush, MD

For decades, the standard of care in rheumatology has been combination therapy - pairing methotrexate (MTX) with an advanced biologic or synthetic agent to achieve optimal outcomes. 

Read Article
https://t.co/4UQlqwujiR 2026 brought together leading rheumatology experts for two days of practical, clinically focused education. Now you can watch the full program On Demand. Highlights include: • RA mortality trends and the mucosal hypothesis • IL-23 vs IL-17 inhibitor https://t.co/YMfxa7PDXF

Links:

Dr. John Cush @RheumNow( View Tweet )
Cancer.risk_.jpg

Malignancies Not Increased with Biologic Therapies

Jack Cush, MD

The risk of malignancy in rheumatoid arthritis (RA) patients receiving biologic agents was evaluated by metanalysis of randomized controlled trials (RCTs) and found no significant increased risk of malignancy compared with other disease-modifying antirheumatic drugs (DMARDs) or with placebo

Read Article

Therapeutic Updates

5-Year Results of an IL-23 Inhibitor in Patients With PsA

AbbVie March 2026
Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.
Read Post

Recent Blogs

Best of 2022: The Enthesitis Challenge in Psoriatic Arthritis

Robert Chao, MD
heel enthesitis spur calcaneal
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do! 
Read Post

Best of 2022: Toss of a Coin - How do You Choose PsA Medication?

M. Elaine Husni, MD, MPH
Coin toss
When balancing all these disease domains, individual phenotypes, and comorbidities, sometimes treatment decisions can feel like tossing a coin. Fortunately, numerous guidelines have been published to help us do better than tossing a coin…or do they? 
Read Post

2021 GRAPPA Recommendations - Looking Back, Looking Forward

Artie Kavanaugh, MD
reflections,ripple
With the recent publication of the third iteration of the GRAPPA Psoriatic Arthritis (PsA) treatment recommendations, it seems to be an auspicious time to reflect on some key considerations that arose during the development of the recommendations, as well as to look towards what the future may hold.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • EULAR 2026 Daily Podcast Day 4c
  • EULAR 2021 - Day2c 00:37:25
×